Download PDF
Semin Respir Crit Care Med 2011; 32(4): 423-432
DOI: 10.1055/s-0031-1283282
© Thieme Medical Publishers

Respiratory Syncytial Virus Infection in Adults

Edward E. Walsh1 , 2
  • 1Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
  • 2Rochester General Hospital, Rochester, New York
Further Information

Publication History

Publication Date:
19 August 2011 (online)

    Permissions and Reprints

ABSTRACT

Respiratory syncytial virus (RSV), an enveloped RNA virus in the Paramyxovirus family, is the most important cause of lower respiratory tract infection in infants and young children, accounting for ~100,000 pediatric hospitalizations and 250 deaths annually in the United States. Despite primarily being recognized as a pediatric pathogen, RSV reinfection causes substantial disease in all adult populations, including healthy young persons, old and frail individuals, those with chronic obstructive pulmonary disease and immunocompromised patients. Most illnesses are mild in adults, but significant morbidity and mortality can develop. In contrast to infants, diagnosis of RSV infections is difficult due to low virus shedding, and optimal diagnosis requires molecular tests. Unfortunately, antiviral therapy is of limited benefit. Ribavirin and palivizumab are the only approved pharmacological agents for RSV treatment and prophylaxis, respectively, and are primarily used in infants; data regarding their usefulness in adults are limited. Currently, specific antiviral therapy is generally reserved for severely immunocompromised patients or severe respiratory failure. The greatest promise for reducing the impact of RSV in adults may be through immunization. However, an effective vaccine for RSV is not currently available.

KEYWORDS

Respiratory syncytial virus - RSV - palivizumab - respiratory viral infections

REFERENCES

  • 1 Blount Jr R E, Morris J A, Savage R E. Recovery of cytopathogenic agent from chimpanzees with coryza.  Proc Soc Exp Biol Med. 1956;  92 (3) 544-549
    PubMedGoogle Scholar
  • 2 Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization.  Am J Hyg. 1957;  66 (3) 281-290
    PubMedGoogle Scholar
  • 3 Kim H W, Arrobio J O, Brandt C D et al.. Epidemiology of respiratory syncytial virus infection in Washington, D.C., I: Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection.  Am J Epidemiol. 1973;  98 (3) 216-225
    PubMedGoogle Scholar
  • 4 Parrott R H, Kim H W, Arrobio J O et al.. Epidemiology of respiratory syncytial virus infection in Washington, D.C., II: Infection and disease with respect to age, immunologic status, race and sex.  Am J Epidemiol. 1973;  98 (4) 289-300
    PubMedGoogle Scholar
  • 5 Brandt C D, Kim H W, Arrobio J O et al.. Epidemiology of respiratory syncytial virus infection in Washington, D.C., III: Composite analysis of eleven consecutive yearly epidemics.  Am J Epidemiol. 1973;  98 (5) 355-364
    PubMedGoogle Scholar
  • 6 Nokes D J, Okiro E A, Ngama M et al.. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life.  J Infect Dis. 2004;  190 (10) 1828-1832
    CrossrefPubMedGoogle Scholar
  • 7 Nair H, Nokes D J, Gessner B D et al.. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.  Lancet. 2010;  375 (9725) 1545-1555
    CrossrefPubMedGoogle Scholar
  • 8 Shay D K, Holman R C, Newman R D, Liu L L, Stout J W, Anderson L J. Bronchiolitis-associated hospitalizations among US children, 1980–1996.  JAMA. 1999;  282 (15) 1440-1446
    CrossrefPubMedGoogle Scholar
  • 9 Zambon M C, Stockton J D, Clewley J P, Fleming D M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study.  Lancet. 2001;  358 (9291) 1410-1416
    CrossrefPubMedGoogle Scholar
  • 10 Falsey A R, Hennessey P A, Formica M A, Cox C, Walsh E E. Respiratory syncytial virus infection in elderly and high-risk adults.  N Engl J Med. 2005;  352 (17) 1749-1759
    CrossrefPubMedGoogle Scholar
  • 11 Collins P L, Murphy B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.  Proc Am Thorac Soc. 2005;  2 (2) 166-173
    CrossrefPubMedGoogle Scholar
  • 12 Collins P L, Murphy B R. Vaccines against human respiratory syncytial virus. In: Cane P A, ed. Respiratory Syncytial Virus. Amsterdam: Elsevier; 2007: 233
    Google Scholar
  • 13 Iwane M K, Edwards K M, Szilagyi P G New Vaccine Surveillance Network et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children.  Pediatrics. 2004;  113 (6) 1758-1764
    CrossrefPubMedGoogle Scholar
  • 14 Collins P L, Graham B S. Viral and host factors in human respiratory syncytial virus pathogenesis.  J Virol. 2008;  82 (5) 2040-2055
    CrossrefPubMedGoogle Scholar
  • 15 Walsh E E, Schlesinger J J, Brandriss M W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies.  Infect Immun. 1984;  43 (2) 756-758
    PubMedGoogle Scholar
  • 16 Johnson P R, Spriggs M K, Olmsted R A, Collins P L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.  Proc Natl Acad Sci U S A. 1987;  84 (16) 5625-5629
    CrossrefPubMedGoogle Scholar
  • 17 Collarini E J, Lee F E, Foord O et al.. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.  J Immunol. 2009;  183 (10) 6338-6345
    CrossrefPubMedGoogle Scholar
  • 18 Haynes L M, Caidi H, Radu G U et al.. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.  J Infect Dis. 2009;  200 (3) 439-447
    CrossrefPubMedGoogle Scholar
  • 19 Harcourt J, Alvarez R, Jones L P, Henderson C, Anderson L J, Tripp R A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1 + T cell responses.  J Immunol. 2006;  176 (3) 1600-1608
    CrossrefPubMedGoogle Scholar
  • 20 Harcourt J L, Karron R A, Tripp R A. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.  J Infect Dis. 2004;  190 (11) 1936-1940
    CrossrefPubMedGoogle Scholar
  • 21 Sullender W M, Mufson M A, Prince G A, Anderson L J, Wertz G W. Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children.  J Infect Dis. 1998;  178 (4) 925-932
    CrossrefPubMedGoogle Scholar
  • 22 Mufson M A, Belshe R B, Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections.  J Clin Microbiol. 1987;  25 (8) 1535-1539
    PubMedGoogle Scholar
  • 23 Hall C B, Walsh E E, Schnabel K C et al.. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children.  J Infect Dis. 1990;  162 (6) 1283-1290
    CrossrefPubMedGoogle Scholar
  • 24 McConnochie K M, Hall C B, Walsh E E, Roghmann K J. Variation in severity of respiratory syncytial virus infections with subtype.  J Pediatr. 1990;  117 (1 Pt 1) 52-62
    CrossrefPubMedGoogle Scholar
  • 25 Hall C B, Douglas Jr R G, Schnabel K C, Geiman J M. Infectivity of respiratory syncytial virus by various routes of inoculation.  Infect Immun. 1981;  33 (3) 779-783
    PubMedGoogle Scholar
  • 26 Lee F E, Walsh E E, Falsey A R et al.. The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFNgamma in young and healthy-elderly subjects.  Mech Ageing Dev. 2005;  126 (11) 1223-1229
    CrossrefPubMedGoogle Scholar
  • 27 Falsey A R, Treanor J J, Betts R F, Walsh E E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings.  J Am Geriatr Soc. 1992;  40 (2) 115-119
    CrossrefPubMedGoogle Scholar
  • 28 Falsey A R, Formica M A, Treanor J J, Walsh E E. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding.  J Clin Microbiol. 2003;  41 (9) 4160-4165
    CrossrefPubMedGoogle Scholar
  • 29 Weinberg G A, Erdman D D, Edwards K M New Vaccine Surveillance Network Study Group et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children.  J Infect Dis. 2004;  189 (4) 706-710
    CrossrefPubMedGoogle Scholar
  • 30 Subbarao E K, Whitehurst N J, Waner J L. Comparison of two enzyme-linked immunosorbent assay (EIA) kits with immunofluorescence and isolation in cell culture for detection of respiratory syncytial virus (RSV).  Diagn Microbiol Infect Dis. 1987;  8 (4) 229-234
    CrossrefPubMedGoogle Scholar
  • 31 Ahluwalia G S, Hammond G W. Comparison of cell culture and three enzyme-linked immunosorbent assays for the rapid diagnosis of respiratory syncytial virus from nasopharyngeal aspirate and tracheal secretion specimens.  Diagn Microbiol Infect Dis. 1988;  9 (3) 187-192
    CrossrefPubMedGoogle Scholar
  • 32 Hall W J, Hall C B, Speers D M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies.  Ann Intern Med. 1978;  88 (2) 203-205
    PubMedGoogle Scholar
  • 33 Duncan C B, Walsh E E, Peterson D R, Lee F E, Falsey A R. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults.  J Infect Dis. 2009;  200 (8) 1242-1246
    CrossrefPubMedGoogle Scholar
  • 34 Falsey A R, Formica M A, Walsh E E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness.  J Clin Microbiol. 2002;  40 (3) 817-820
    CrossrefPubMedGoogle Scholar
  • 35 Englund J A, Piedra P A, Jewell A, Patel K, Baxter B B, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults.  J Clin Microbiol. 1996;  34 (7) 1649-1653
    PubMedGoogle Scholar
  • 36 Casiano-Colón A E, Hulbert B B, Mayer T K, Walsh E E, Falsey A R. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults.  J Clin Virol. 2003;  28 (2) 169-174
    CrossrefPubMedGoogle Scholar
  • 37 Walsh E E, Falsey A R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults.  J Med Virol. 2004;  73 (2) 295-299
    CrossrefPubMedGoogle Scholar
  • 38 Hall C B, Kopelman A E, Douglas Jr R G, Geiman J M, Meagher M P. Neonatal respiratory syncytial virus infection.  N Engl J Med. 1979;  300 (8) 393-396
    CrossrefPubMedGoogle Scholar
  • 39 Nicholson K G, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden.  BMJ. 1997;  315 (7115) 1060-1064
    CrossrefPubMedGoogle Scholar
  • 40 Nicholson K G. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990.  Epidemiol Infect. 1996;  116 (1) 51-63
    CrossrefPubMedGoogle Scholar
  • 41 Griffin M R, Coffey C S, Neuzil K M, Mitchel Jr E F, Wright P F, Edwards K M. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease.  Arch Intern Med. 2002;  162 (11) 1229-1236
    CrossrefPubMedGoogle Scholar
  • 42 Mullooly J P, Bridges C B, Thompson W W Vaccine Safety Datalink Adult Working Group et al. Influenza- and RSV-associated hospitalizations among adults.  Vaccine. 2007;  25 (5) 846-855
    CrossrefPubMedGoogle Scholar
  • 43 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States.  JAMA. 2003;  289 (2) 179-186
    CrossrefPubMedGoogle Scholar
  • 44 Hall C B, Long C E, Schnabel K C. Respiratory syncytial virus infections in previously healthy working adults.  Clin Infect Dis. 2001;  33 (6) 792-796
    CrossrefPubMedGoogle Scholar
  • 45 Hall W J, Hall C B, Speers D M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies.  Ann Intern Med. 1978;  88 (2) 203-205
    PubMedGoogle Scholar
  • 46 Falsey A R, Cunningham C K, Barker W H et al.. Respiratory syncytial virus and influenza A infections in the hospitalized elderly.  J Infect Dis. 1995;  172 (2) 389-394
    CrossrefPubMedGoogle Scholar
  • 47 Hutchinson A F, Ghimire A K, Thompson M A et al.. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD.  Respir Med. 2007;  101 (12) 2472-2481
    CrossrefPubMedGoogle Scholar
  • 48 De Serres G, Lampron N, La Forge J et al.. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations.  J Clin Virol. 2009;  46 (2) 129-133
    CrossrefPubMedGoogle Scholar
  • 49 Camargo Jr C A, Ginde A A, Clark S, Cartwright C P, Falsey A R, Niewoehner D E. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease.  Intern Emerg Med. 2008;  3 (4) 355-359
    CrossrefPubMedGoogle Scholar
  • 50 Ko F W, Ip M, Chan P K et al.. Viral etiology of acute exacerbations of COPD in Hong Kong.  Chest. 2007;  132 (3) 900-908
    CrossrefPubMedGoogle Scholar
  • 51 Beckham J D, Cadena A, Lin J et al.. Respiratory viral infections in patients with chronic, obstructive pulmonary disease.  J Infect. 2005;  50 (4) 322-330
    CrossrefPubMedGoogle Scholar
  • 52 Rohde G, Wiethege A, Borg I et al.. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study.  Thorax. 2003;  58 (1) 37-42
    CrossrefPubMedGoogle Scholar
  • 53 Falsey A R, Formica M A, Hennessey P A, Criddle M M, Sullender W M, Walsh E E. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2006;  173 (6) 639-643
    PubMedGoogle Scholar
  • 54 Wilkinson T M, Donaldson G C, Johnston S L, Openshaw P J, Wedzicha J A. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2006;  173 (8) 871-876
    CrossrefPubMedGoogle Scholar
  • 55 Sikkel M B, Quint J K, Mallia P, Wedzicha J A, Johnston S L. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease.  Pediatr Infect Dis J. 2008;  27 (10, Suppl) S63-S70
    PubMedGoogle Scholar
  • 56 Borg I, Rohde G, Löseke S et al.. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases.  Eur Respir J. 2003;  21 (6) 944-951
    CrossrefPubMedGoogle Scholar
  • 57 Nicholson K G, McNally T, Silverman M, Simons P, Stockton J D, Zambon M C. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children.  Vaccine. 2006;  24 (1) 102-108
    CrossrefPubMedGoogle Scholar
  • 58 Dowell S F, Anderson L J, Gary Jr H E et al.. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults.  J Infect Dis. 1996;  174 (3) 456-462
    CrossrefPubMedGoogle Scholar
  • 59 Walsh E E, Peterson D R, Falsey A R. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?.  J Infect Dis. 2007;  195 (7) 1046-1051
    CrossrefPubMedGoogle Scholar
  • 60 DeVincenzo J P, Wilkinson T, Vaishnaw A et al.. Viral load drives disease in humans experimentally infected with respiratory syncytial virus.  Am J Respir Crit Care Med. 2010;  182 (10) 1305-1314
    CrossrefPubMedGoogle Scholar
  • 61 DeVincenzo J P, El Saleeby C M, Bush A J. Respiratory syncytial virus load predicts disease severity in previously healthy infants.  J Infect Dis. 2005;  191 (11) 1861-1868
    CrossrefPubMedGoogle Scholar
  • 62 Buckingham S C, Bush A J, Devincenzo J P. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants.  Pediatr Infect Dis J. 2000;  19 (2) 113-117
    PubMedGoogle Scholar
  • 63 Houben M L, Coenjaerts F E, Rossen J W et al.. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community.  J Med Virol. 2010;  82 (7) 1266-1271
    CrossrefPubMedGoogle Scholar
  • 64 Walsh E E, Peterson D R, Falsey A R. Risk factors for severe respiratory syncytial virus infection in elderly persons.  J Infect Dis. 2004;  189 (2) 233-238
    CrossrefPubMedGoogle Scholar
  • 65 Falsey A R. Noninfluenza respiratory virus infection in long-term care facilities.  Infect Control Hosp Epidemiol. 1991;  12 (10) 602-608
    CrossrefPubMedGoogle Scholar
  • 66 Mathur U, Bentley D W, Hall C B. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill.  Ann Intern Med. 1980;  93 (1) 49-52
    PubMedGoogle Scholar
  • 67 Caram L B, Chen J, Taggart E W et al.. Respiratory syncytial virus outbreak in a long-term care facility detected using reverse transcriptase polymerase chain reaction: an argument for real-time detection methods.  J Am Geriatr Soc. 2009;  57 (3) 482-485
    CrossrefPubMedGoogle Scholar
  • 68 Drinka P J, Gravenstein S, Krause P et al.. Non-influenza respiratory viruses may overlap and obscure influenza activity.  J Am Geriatr Soc. 1999;  47 (9) 1087-1093
    PubMedGoogle Scholar
  • 69 Ellis S E, Coffey C S, Mitchel Jr E F, Dittus R S, Griffin M R. Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population.  J Am Geriatr Soc. 2003;  51 (6) 761-767
    CrossrefPubMedGoogle Scholar
  • 70 Falsey A R, McCann R M, Hall W J et al.. Acute respiratory tract infection in daycare centers for older persons.  J Am Geriatr Soc. 1995;  43 (1) 30-36
    CrossrefPubMedGoogle Scholar
  • 71 Wendt C H, Hertz M I. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.  Semin Respir Infect. 1995;  10 (4) 224-231
    PubMedGoogle Scholar
  • 72 McColl M D, Corser R B, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin.  Bone Marrow Transplant. 1998;  21 (4) 423-425
    CrossrefPubMedGoogle Scholar
  • 73 Mazzulli T, Peret T C, McGeer A et al.. Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward.  J Infect Dis. 1999;  180 (5) 1686-1689
    CrossrefPubMedGoogle Scholar
  • 74 Whimbey E, Champlin R E, Couch R B et al.. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients.  Clin Infect Dis. 1996;  22 (5) 778-782
    CrossrefPubMedGoogle Scholar
  • 75 Whimbey E, Couch R B, Englund J A et al.. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia.  Clin Infect Dis. 1995;  21 (2) 376-379
    CrossrefPubMedGoogle Scholar
  • 76 Englund J A, Anderson L J, Rhame F S. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults.  J Clin Microbiol. 1991;  29 (1) 115-119
    PubMedGoogle Scholar
  • 77 Hertz M I, Englund J A, Snover D, Bitterman P B, McGlave P B. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature.  Medicine (Baltimore). 1989;  68 (5) 269-281
    PubMedGoogle Scholar
  • 78 Englund J A, Sullivan C J, Jordan M C, Dehner L P, Vercellotti G M, Balfour Jr H H. Respiratory syncytial virus infection in immunocompromised adults.  Ann Intern Med. 1988;  109 (3) 203-208
    PubMedGoogle Scholar
  • 79 Shah J N, Chemaly R F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation.  Blood. 2011;  117 (10) 2755-2763
    CrossrefPubMedGoogle Scholar
  • 80 Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients.  Br J Haematol. 2008;  143 (4) 455-467
    PubMedGoogle Scholar
  • 81 Erard V, Chien J W, Kim H W et al.. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses.  J Infect Dis. 2006;  193 (12) 1619-1625
    CrossrefPubMedGoogle Scholar
  • 82 Kim Y J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection.  Semin Respir Crit Care Med. 2007;  28 (2) 222-242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Zamora M R, Budev M, Rolfe M et al.. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.  Am J Respir Crit Care Med. 2011;  183 (4) 531-538
    CrossrefPubMedGoogle Scholar
  • 84 Kumar D, Erdman D, Keshavjee S et al.. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.  Am J Transplant. 2005;  5 (8) 2031-2036
    CrossrefPubMedGoogle Scholar
  • 85 Glezen W P, Paredes A, Allison J E, Taber L H, Frank A L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.  J Pediatr. 1981;  98 (5) 708-715
    CrossrefPubMedGoogle Scholar
  • 86 Carbonell-Estrany X, Simões E A, Dagan R Motavizumab Study Group et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.  Pediatrics. 2010;  125 (1) e35-e51
    CrossrefPubMedGoogle Scholar
  • 87 IMpact-RSV Study Group . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.  Pediatrics. 1998;  102 (3) 531-537
    CrossrefPubMedGoogle Scholar
  • 88 Malley R, DeVincenzo J, Ramilo O et al.. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.  J Infect Dis. 1998;  178 (6) 1555-1561
    CrossrefPubMedGoogle Scholar
  • 89 Lee F E, Walsh E E, Falsey A R, Betts R F, Treanor J J. Experimental infection of humans with A2 respiratory syncytial virus.  Antiviral Res. 2004;  63 (3) 191-196
    CrossrefPubMedGoogle Scholar
  • 90 Mills J V, Van Kirk J E, Wright P F, Chanock R M. Experimental respiratory syncytial virus infection of adults: possible mechanisms of resistance to infection and illness.  J Immunol. 1971;  107 (1) 123-130
    PubMedGoogle Scholar
  • 91 Hall C B, Walsh E E, Long C E, Schnabel K C. Immunity to and frequency of reinfection with respiratory syncytial virus.  J Infect Dis. 1991;  163 (4) 693-698
    CrossrefPubMedGoogle Scholar
  • 92 Walsh E E, Falsey A R. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults.  J Infect Dis. 2004;  190 (2) 373-378
    CrossrefPubMedGoogle Scholar
  • 93 Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al.. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.  J Virol. 2006;  80 (3) 1130-1139
    CrossrefPubMedGoogle Scholar
  • 94 Johnson T R, Mertz S E, Gitiban N et al.. Role for innate IFNs in determining respiratory syncytial virus immunopathology.  J Immunol. 2005;  174 (11) 7234-7241
    PubMedGoogle Scholar
  • 95 Villenave R, O'Donoghue D, Thavagnanam S et al.. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells.  Virol J. 2011;  8 (1) 43
    CrossrefPubMedGoogle Scholar
  • 96 Thornburg N J, Shepherd B, Crowe Jr J E. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection.  J Virol. 2010;  84 (24) 12895-12902
    CrossrefPubMedGoogle Scholar
  • 97 Oshansky C M, Barber J P, Crabtree J, Tripp R A. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells.  J Infect Dis. 2010;  201 (8) 1201-1207
    CrossrefPubMedGoogle Scholar
  • 98 Oshansky C M, Zhang W, Moore E, Tripp R A. The host response and molecular pathogenesis associated with respiratory syncytial virus infection.  Future Microbiol. 2009;  4 (3) 279-297
    CrossrefPubMedGoogle Scholar
  • 99 Halfhide C P, Brearey S P, Flanagan B F et al.. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis.  Thorax. 2009;  64 (9) 798-805
    CrossrefPubMedGoogle Scholar
  • 100 Lukens M V, van de Pol A C, Coenjaerts F E et al.. A systemic neutrophil response precedes robust CD8( + ) T-cell activation during natural respiratory syncytial virus infection in infants.  J Virol. 2010;  84 (5) 2374-2383
    CrossrefPubMedGoogle Scholar
  • 101 Miyairi I, DeVincenzo J P. Human genetic factors and respiratory syncytial virus disease severity.  Clin Microbiol Rev. 2008;  21 (4) 686-703
    CrossrefPubMedGoogle Scholar
  • 102 Janssen R, Bont L, Siezen C L et al.. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.  J Infect Dis. 2007;  196 (6) 826-834
    CrossrefPubMedGoogle Scholar
  • 103 Kapikian A Z, Mitchell R H, Chanock R M, Shvedoff R A, Stewart C E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.  Am J Epidemiol. 1969;  89 (4) 405-421
    PubMedGoogle Scholar
  • 104 Lee D C, Harker J A, Tregoning J S et al.. CD25 + natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection.  J Virol. 2010;  84 (17) 8790-8798
    CrossrefPubMedGoogle Scholar
  • 105 Welliver T P, Reed J L, Welliver Sr R CS. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases.  Pediatr Infect Dis J. 2008;  27 (10, Suppl) S92-S96
    PubMedGoogle Scholar
  • 106 Welliver T P, Garofalo R P, Hosakote Y et al.. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses.  J Infect Dis. 2007;  195 (8) 1126-1136
    CrossrefPubMedGoogle Scholar
  • 107 Looney R J, Falsey A R, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection.  J Infect Dis. 2002;  185 (5) 682-685
    CrossrefPubMedGoogle Scholar
  • 108 Groothuis J R, Woodin K A, Katz R et al.. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children.  J Pediatr. 1990;  117 (5) 792-798
    CrossrefPubMedGoogle Scholar
  • 109 Hall C B, McBride J T, Gala C L, Hildreth S W, Schnabel K C. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease.  JAMA. 1985;  254 (21) 3047-3051
    CrossrefPubMedGoogle Scholar
  • 110 Englund J A, Piedra P A, Jefferson L S, Wilson S Z, Taber L H, Gilbert B E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection.  J Pediatr. 1990;  117 (2 Pt 1) 313-320
    CrossrefPubMedGoogle Scholar
  • 111 American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis . Diagnosis and management of bronchiolitis.  Pediatrics. 2006;  118 (4) 1774-1793
    CrossrefPubMedGoogle Scholar
  • 112 The PREVENT Study Group . Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis.  Pediatrics. 1997;  99 (1) 93-99
    CrossrefPubMedGoogle Scholar
  • 113 Zempsky W T, Schechter N L. IMpact-RSV study group report.  Pediatrics. 1999;  104 (4 Pt 1) 993-994 author reply 995
    CrossrefPubMedGoogle Scholar
  • 114 Lee F E, Walsh E E, Falsey A R. The effect of steroid use in hospitalized adults with respiratory syncytial virus related illness.  Chest. 2011 May 12. [Epub ahead of print]
    PubMedGoogle Scholar
  • 115 Chemaly R F, Ghosh S, Bodey G P et al.. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center.  Medicine (Baltimore). 2006;  85 (5) 278-287
    CrossrefPubMedGoogle Scholar
  • 116 Torres H A, Aguilera E A, Mattiuzzi G N et al.. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia.  Haematologica. 2007;  92 (9) 1216-1223
    CrossrefPubMedGoogle Scholar
  • 117 Empey K M, Peebles Jr R S, Kolls J K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.  Clin Infect Dis. 2010;  50 (9) 1258-1267
    CrossrefPubMedGoogle Scholar
  • 118 Murata Y. Respiratory syncytial virus vaccine development.  Clin Lab Med. 2009;  29 (4) 725-739
    CrossrefPubMedGoogle Scholar
  • 119 Gonzalez I M, Karron R A, Eichelberger M et al.. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.  Vaccine. 2000;  18 (17) 1763-1772
    CrossrefPubMedGoogle Scholar
  • 120 Falsey A R, Walsh E E, Capellan J et al.. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals.  J Infect Dis. 2008;  198 (9) 1317-1326
    CrossrefPubMedGoogle Scholar
  • 121 Falsey A R, Walsh E E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.  Vaccine. 1996;  14 (13) 1214-1218
    CrossrefPubMedGoogle Scholar

Edward E WalshM.D. 

Department of Medicine, University of Rochester School of Medicine and Dentistry

1425 Portland Ave., Rochester, NY 14621

Email: edward.walsh@rochestergeneral.org